Evidence map›Paper›PMID 21699934›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2011

Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics.

William B Liechty, Mary Caldorera-Moore, Margaret A Phillips, Cody Schoener, Nicholas A Peppas

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Novel PLGA-based nanoparticles for the oral delivery of insulin.International journal of nanomedicine · 2015
    Article
  14. Hydrogels and scaffolds for immunomodulation.Advanced materials (Deerfield Beach, Fla.) · 2014
    Review
  15. Review
  16. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2013
    Review
  17. Expert opinion: Responsive polymer nanoparticles in cancer therapy.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2012
    Review
  18. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2012
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

William B LiechtyDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
Mary Caldorera-Moore
Margaret A Phillips
Cody Schoener
Nicholas A Peppas

Funding

TRANS-NETWORK PROJECTSU54CA143837 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2009 to 2014
$10.8M
pH Sensitive Complex Hydrogels for Protein Drug ReleaseR01EB000246 · NIBIB · UNIVERSITY OF TEXAS AUSTIN · PI LOWMAN, ANTHONY M, PEPPAS, NICHOLAS A · 2002 to 2014
$3.8M
PH-SENSITIVE HYDROGELS FOR DRUG RELEASER01GM043337 · NIGMS · PURDUE UNIVERSITY WEST LAFAYETTE · PI PEPPAS, NICHOLAS A · 1990 to 2001
$590k
NCI NIH HHS U54 CA143837NCI NIH HHS U54-CA-143837NIBIB NIH HHS R01 EB000246NIGMS NIH HHS R01 GM043337
6 · The paper itself

Abstract

Hydrogels have been instrumental in the development of polymeric systems for controlled release of therapeutic agents. These materials are attractive for transmucosal and intracellular drug delivery because of their facile synthesis, inherent biocompatibility, tunable physicochemical properties, and capacity to respond to various physiological stimuli. In this contribution, we outline a multifaceted hydrogel-based approach for expanding the range of therapeutics in oral formulations from classical small-molecule drugs to include proteins, chemotherapeutics, and nucleic acids. Through judicious material selection and careful design of copolymer composition and molecular architecture, we can engineer systems capable of responding to distinct physiological cues, with tunable physicochemical properties that are optimized to load, protect, and deliver valuable macromolecular payloads to their intended site of action. These hydrogel carriers, including complexation hydrogels, tethered hydrogels, interpenetrating networks, nanoscale hydrogels, and hydrogels with decorated structures are investigated for their ability to respond to changes in pH, to load and release insulin and fluorescein, and remain non-toxic to Caco-2 cells. Our results suggest these novel hydrogel networks have great potential for controlled delivery of proteins, chemotherapeutics, and nucleic acids.

Indexed as

Antineoplastic AgentsBiocompatible MaterialsBiopolymersCaco-2 CellsCell SurvivalDrug CarriersDrug CompoundingHumansHydrogelsHydrogen-Ion ConcentrationLightMicroscopy, Electron, ScanningMicroscopy, Electron, TransmissionMouth MucosaNeoplasmsNucleic AcidsAntineoplastic AgentsBiocompatible MaterialsBiopolymersDrug CarriersHydrogelsNucleic AcidsPharmaceutical PreparationsProteins

Identifiers

PMID21699934
PMCPMC3195952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.